Autonomix Medical

Autonomix is testing a minimally invasive nerve ablation platform for treating severe pancreatic cancer pain in a first-in-human clinical trial.

Autonomix develops a precision-guided platform for nerve-sensing, ablation, and verification in the $100 billion global electrophysiology market.

Autonomix’s custom-designed sensing antenna array detects signals below 5 µV using prototype electrodes as small as 0.02 mm x 0.03 mm.

Mr. Klemp is a serial entrepreneur with multiple successful exits, including serving as CEO of Soliton, Inc., which he co-founded, took public on Nasdaq in 2018, and was acquired by AbbVie in 2021.

The company has over 80 years of combined experience in medical devices and has developed technologies like the Watchman cardiology device, invented by Dr. Robert Schwartz and acquired by Boston Scientific in 2011, and the Resonic cellulite treatment, acquired by AbbVie in 2021.

Autonomix Medical, Inc. 21 Waterway Ave, Suite 300 The Woodlands, TX 77380

Autonomix’s platform provides real-time, intra-procedural nerve mapping, enabling physicians to sense nerve activity and guide precise treatment in transvascular denervation.

Autonomix outlines privacy practices for collecting, using, and protecting personal information on its website and services.

Autonomix Medical expands patent coverage for its catheter-based platform, which facilitates transvascular access, adaptive treatment delivery, and real-time procedural validation beyond vessel walls. The technology integrates treatment guidance and validation capabilities to enhance precision in medical interventions. The updated patents reinforce protection for core functionalities of the company’s platform.

Oct 2026GlobeNewswireNews article

Autonomix receives positive feedback from the FDA on its 510(k) submission, confirming a **Class II device classification** with **substantial equivalence** to an existing cleared product. This feedback accelerates the company’s path toward **U.S. market clearance** for its standalone sensing platform, targeting an estimated **15-month timeline** for initial approval.

Sep 2026GlobeNewswireNews article

Autonomix Medical secures a European patent for its proprietary autonomic nervous system assessment technologies, reinforcing its precision neuromodulation platform. The patent bolsters the company’s international intellectual property portfolio, enabling broader legal protection for its innovations in neuromodulation.

Sep 2026GlobeNewswireNews article

Autonomix Medical adds Sandra Cohen Kalter, former Medtronic Chief Regulatory Counsel, to its board of directors. Cohen Kalter brings over four decades of MedTech leadership, FDA regulatory expertise, and experience supporting transformative technologies like renal denervation. Her appointment strengthens the company’s strategic and compliance capabilities in medical device innovation.

Sep 2026GlobeNewswireNews article